<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372501</url>
  </required_header>
  <id_info>
    <org_study_id>09-3</org_study_id>
    <nct_id>NCT01372501</nct_id>
  </id_info>
  <brief_title>Study of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner</brief_title>
  <official_title>A Pilot Trial of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GI Dynamics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the GI Endobarrier Liner can be
      reimplanted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with obesity are at significantly greater risk of developing significant co-morbid
      complications, and are associated with an increased risk in all-cause mortality. The GI
      Endobarrier Liner represents a viable alternative to other short-term weight loss methods. It
      is a minimally invasive endoscopic procedure, which may allow patients to recover faster with
      less morbidity and mortality. This study is investigating whether the the GI Endobarrier
      Liner can be reimplanted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the % Excess Weight Loss at Week 52 or Last Assessment</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Excess weight was determined from ideal body weights based on a BMI of 25 kg/m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Absolute Weight Loss From Baseline to Week 52</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Experimental: Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be implanted with the Endobarrier Liner device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endobarrier Liner</intervention_name>
    <description>Medical device placed endoscopically in the duodenum</description>
    <arm_group_label>Experimental: Device</arm_group_label>
    <other_name>GI Sleeve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and &lt; 55 years - Male or Female

          -  Previously implanted with the EndoBarrier Gastrointestinal Liner

          -  Subjects willing to comply with trial requirements

          -  Subjects who have signed an informed consent form

          -  Women who are post-menopausal, surgically sterile or on oral contraceptives for the
             duration of the study and who do not plan on becoming pregnant during the course of
             the trial.

        Exclusion Criteria:

          -  Treatment represents an unreasonable risk to the subject

          -  Pregnant or have intention of becoming pregnant for the duration of the trial

          -  Unresolved alcohol or drug addiction

          -  Subjects receiving weight loss medications (prescription, over-the- counter, or herbal
             dietary medications)

          -  Previous gastrointestinal surgery that could affect the ability to place the
             EndoBarrier Liner or the function of the implant.

          -  Subjects with active and uncontrolled gastroesophageal reflux disease (GERD)

          -  Subjects with symptomatic kidney stones prior to implant

          -  Subjects taking corticosteroids or drugs known to affect GI motility (i.e. Reglan)

          -  Subjects with iron deficiency and/or iron deficiency anemia

          -  History of Inflammatory bowel disease or condition of the gastrointestinal tract, such
             as ulcers or Crohn's disease

          -  Subjects with symptomatic gallstones prior to implant

          -  Symptomatic coronary artery disease or pulmonary dysfunction

          -  Known infection (Subjects who have a known infection at time of screening can be
             enrolled if the infection is treated prior to their procedure; if they still have an
             infection on day of procedure they must be withdrawn)

          -  History of congenital or acquired anomalies of the gastrointestinal tract such as
             atresias or stenoses

          -  Pancreatitis or other serious organic conditions

          -  Subjects requiring prescription anticoagulation therapy

          -  Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during
             the implant period

          -  Subject or Family history of a known diagnosis or pre-existing symptoms of systemic
             lupus erythematosus, scleroderma or other autoimmune connective tissue disorder

          -  Participating in another ongoing investigational clinical trial

          -  Mentally retarded or emotionally unstable, or exhibits psychological characteristics
             requiring medication that affects appetite (i.e. tricyclic antidepressants and
             atypical antipsychotic medications) which, in the opinion of the Investigator, makes
             the subject a poor candidate for device placement or clinical trial.

          -  Subjects with active H. pylori (Note: Subjects may be enrolled if they had a prior
             history of H. Pylori and were successfully treated or are diagnosed during baseline
             tests and undergo successful treatment before their procedure)

          -  Subjects with or a history of coagulopathy, upper gastro-intestinal bleeding
             conditions such as esophageal or gastric varices, congenital or acquired intestinal
             telangiectasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex P Escalona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile, Santiago, Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Alex P Escalona</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <results_first_submitted>February 13, 2016</results_first_submitted>
  <results_first_submitted_qc>February 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2016</results_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual data is available on site at Sponsor</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EndoBarrier Liner Device</title>
          <description>All patients will be implanted with the Endobarrier Liner device.
Endobarrier Liner: Medical device placed endoscopically in the duodenum</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Device migration</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EndoBarrier Liner Device</title>
          <description>All patients will be implanted with the Endobarrier Liner device
Endobarrier Liner: Medical device placed endoscopically in the duodenum</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of the % Excess Weight Loss at Week 52 or Last Assessment</title>
        <description>Excess weight was determined from ideal body weights based on a BMI of 25 kg/m2</description>
        <time_frame>52 Weeks</time_frame>
        <population>Full Analysis Set (FAS) population had a device successfully implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>EndoBarrier Liner Device</title>
            <description>All patients will be implanted with the Endobarrier Liner device
Endobarrier Liner: Medical device placed endoscopically in the duodenum</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of the % Excess Weight Loss at Week 52 or Last Assessment</title>
          <description>Excess weight was determined from ideal body weights based on a BMI of 25 kg/m2</description>
          <population>Full Analysis Set (FAS) population had a device successfully implanted.</population>
          <units>%EWL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="20.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Absolute Weight Loss From Baseline to Week 52</title>
        <time_frame>Week 52</time_frame>
        <population>Per Protocol Population (n=14); subjects who had the device implanted for 52 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>EndoBarrier Liner Device</title>
            <description>Endobarrier Liner: Medical device placed endoscopically in the duodenum</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute Weight Loss From Baseline to Week 52</title>
          <population>Per Protocol Population (n=14); subjects who had the device implanted for 52 weeks.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EndoBarrier Liner Device</title>
          <description>All patients will be implanted with the Endobarrier Liner device
Endobarrier Liner: Medical device placed endoscopically in the duodenum</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="20" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Affairs Manager</name_or_title>
      <organization>GI Dynamics, Inc.</organization>
      <phone>781.357.3261</phone>
      <email>pkeating@gidynamics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

